The US Food and Drug Administration (FDA) approved 2 original drug applications in September 2002. The first is Hepsera (adefovir dipivoxil) for the treatment of chronic hepatitis B. The second is Inspra (eplerenone) for the treatment of hypertension.
Antihypertensives Avapro (irbesartan) and Cozaar (losartan) gained approval for a new indication for use in patients with type 2 diabetes for the treatment of nephropathy.
This month's column reviews FDA new product approvals and labeling changes for these products as well as the following:
Atacand (candesartan cilexetil)
Augmentin XR extended-release tablets
Hepsera (adefovir dipivoxil)
Prevacid SoluTab (lansoprazole)
Fluzone (preservative-free influenza virus vaccine) intramuscular injection
Medscape Pharmacists. 2002;3(2) © 2002 Medscape
Cite this: October 2002 - Medscape - Oct 23, 2002.